{"Clinical Trial ID": "NCT00201851", "Intervention": ["INTERVENTION 1:", "A - Scheduled surgery", "In patients with an oophorectomy/surgical mastectomy in the average luteal phase plus tamoxifen", "Tamoxifene: 20 mg in. per day x 5 years", "Surgery: Oophorectomy: surgical oophorectomy and mastectomy of group A in 5 days in the mean luteal phase of the menstrual cycle (b, c) surgical oophorectomy and mastectomy of group B (1-6 days after randomization)(b, c) surgical oophorectomy and mastectomy of group C (1-6 days after registration)(c)", "INTERVENTION 2:", "B - Immediate surgery", "Patients with immediate oophorectomy/mastectomy and tamoxifen", "Tamoxifene: 20 mg in. per day x 5 years", "Surgery: Oophorectomy: surgical oophorectomy and mastectomy of group A in 5 days in the mean luteal phase of the menstrual cycle (b, c) surgical oophorectomy and mastectomy of group B (1-6 days after randomization)(b, c) surgical oophorectomy and mastectomy of group C (1-6 days after registration)(c)"], "Eligibility": ["Incorporation criteria:", "\u2022 Open for accrual accounting in Asia only", "Women between 18 and 50 years of age,", "Premenopausal with regular cycles (>25-35 length)", "Diagnosis of the aspiration of fine needs", "Stage II-IIIA positive hormone receptor invasive breast cancer", "No previous radiation therapy or chemotherapy", "\u2022 Must be a surgical candidate for a bilateral oophorectomy"], "Results": ["Performance measures:", "\u2022 Disease-free survival", "5 years of disease-free survival", "Time limit: two to three year accrual accounting and initial follow-up period of two or more years", "Results 1:", "Title of arm/group: A - Scheduled surgery", "Description of the arm/group: Patients expected for the oophorectomy/surgical mastectomy in the average luteal phase plus tamoxifen", "Tamoxifene: 20 mg in. per day x 5 years", "Surgery: Oophorectomy: surgical oophorectomy and mastectomy of group A in 5 days in the mean luteal phase of the menstrual cycle (b, c) surgical oophorectomy and mastectomy of group B (1-6 days after randomization)(b, c) surgical oophorectomy and mastectomy of group C (1-6 days after registration)(c)", "Total number of participants analysed: 244", "Type of measurement: Number", "Unit of measure: percentage of participants 64", "Results 2:", "Title of arm/group: B - Immediate surgery", "Description of the arm/group: Patient with immediate oophorectomy/surgical mastectomy and tamoxifen", "Tamoxifene: 20 mg in. per day x 5 years", "Surgery: Oophorectomy: surgical oophorectomy and mastectomy of group A in 5 days in the mean luteal phase of the menstrual cycle (b, c) surgical oophorectomy and mastectomy of group B (1-6 days after randomization)(b, c) surgical oophorectomy and mastectomy of group C (1-6 days after registration)(c)", "Total number of participants analysed: 255", "Type of measurement: Number", "Unit of measure: percentage of participants 71"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/244 (0.00 per cent)", "Pregnancy *0/244 (0.00 %)", "*0/244 (0.00%)", "Nosocomial pneumonia *0/244 (0.00 %)", "\u2022 venous thrombosis *0/244 (0.00%)", "Adverse Events 2:", "Total: 5/255 (1.96%)", "Pregnancy *1/255 (0.39%)", "*1/255 (0.39%)", "Nosocomial pneumonia *2/255 (0.78%)", "\u2022 venous thrombosis *1/255 (0.39%)"]}